Satellos Bioscience Inc.
$7.83
▼
-2.81%
2026-04-21 08:16:01
satellos.com
NGM: MSLE
Explore Satellos Bioscience Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$248.1 M
Current Price
$7.83
52W High / Low
$18.98 / $6.24
Stock P/E
—
Book Value
$1.8
Dividend Yield
—
ROCE
-95.23%
ROE
-66.37%
Face Value
—
EPS
$-20.4
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
18
Beta
1.08
Debt / Equity
—
Current Ratio
7.77
Quick Ratio
7.77
Forward P/E
-1.95
Price / Sales
—
Enterprise Value
$107.69 M
EV / EBITDA
-4.07
EV / Revenue
—
Rating
Strong Buy
Target Price
$30
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Filana Therapeutics, Inc. | $1.75 | — | $84.54 M | — | -128.99% | -82.66% | $2.27 / $1.53 | $1.54 |
| 2. | Ionis Pharmaceuticals, Inc. | $74.84 | — | $12.38 B | — | -13.92% | -70.8% | $86.74 / $27.9 | $3 |
| 3. | Anixa Biosciences, Inc. | $3 | — | $100.58 M | — | -82.91% | -68.06% | $5.46 / $2.44 | $0.45 |
| 4. | Atea Pharmaceuticals, Inc. | $5.71 | — | $457.32 M | — | -65.67% | -44.34% | $6.45 / $2.46 | $3.52 |
| 5. | Zymeworks Inc. | $27.85 | — | $1.98 B | — | -30.42% | -26.72% | $28.49 / $10.86 | $3.6 |
| 6. | Crescent Biopharma, Inc. | $21.69 | — | $575.8 M | — | -74.74% | -1.61% | $29 / $8.72 | $5.99 |
| 7. | Climb Bio, Inc. | $8.97 | — | $437.55 M | — | -42.23% | -32.15% | $9.4 / $1.13 | $3.36 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -7.65 M | -5.97 M | -6.37 M | -6.48 M | -4.58 M | — |
| Net Profit | -7.3 M | -5.82 M | -5.61 M | -6.14 M | -3.3 M | — |
| EPS in Rs | -0.35 | -0.28 | -0.27 | -0.29 | -0.16 | -0.72 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -26.46 M | -20.4 M | -11.66 M | -6.21 M |
| Net Profit | -24.87 M | -20.63 M | -11.98 M | -8.34 M |
| EPS in Rs | -1.19 | -0.99 | -0.57 | -0.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 31.89 M | 50.75 M | 33.49 M | 4.57 M |
| Total Liabilities | 4.11 M | 3.58 M | 2.73 M | 2.09 M |
| Equity | 27.78 M | 47.16 M | 30.76 M | 2.48 M |
| Current Assets | 31.88 M | 50.74 M | 30.48 M | 1.65 M |
| Current Liabilities | 4.11 M | 3.58 M | 2.73 M | 2.09 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -23.6 M | -18.25 M | -8.73 M | -4.26 M |
| Investing CF | -9.42 M | 4.66 M | -13.22 M | -0 M |
| Financing CF | 2.24 M | 37.57 M | 38.01 M | 2.04 M |
| Free CF | -23.6 M | -18.26 M | -8.75 M | -4.26 M |
| Capex | -0.01 M | -0 M | -0.01 M | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -72.28% | -43.57% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-01-30 | 1:0.0833333 |
| 2021-08-18 | 1:0.05 |